
Foresee Pharmaceuticals announced it will deliver the results of its aderamastat (FP-025) phase 2 proof-of-concept allergic asthma study during a late-breaking session at the European Respiratory Society (ERS) International Congress in Milan, Italy, Sept. 9-13.
The session presentation, "Effect of MMP-12 Inhibitor, Aderamastat (FP-025), on Allergen-Induced Late Response in Asthmatic Subjects" is the result of a collaboration with clinical experts in asthma and pulmonology in the Netherlands. It focuses on the primary results from the assessment of the efficacy of multiple oral doses of aderamastat in HDM-allergic asthma patients.
"We are very excited to have the opportunity to present promising data related to the previously announced aderamastat topline phase 2 proof-of-concept study. The data strongly support the role of MMP-12 in key inflammatory pathways that contribute to asthma and other lung diseases," said Yisheng Lee, MD, chief medical officer at Foresee. "With this phase 2 study, our objective was to demonstrate that the inhibition of MMP-12 in humans was in line with the MMP-12 single-nucleotide polymorphism (SNP) data, human expression data and animal pharmacology models. We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung."
Aderamastat is a selective, oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. Aderamastat showed sustained anti-inflammatory effects and attenuated allergen-induced histopathology in a mouse model of house dust-mite (HDM).
"With this recent positive aderamastat phase 2 study, we are excited to shine a light on a novel therapeutic mechanism and are working diligently to build a broad first-in-class/best-in-class franchise leveraging aderamastat” said Ben Chien, PhD, Foresee chairman and CEO. “Our additional MMP-12 inhibitors, including FP-020, across several therapeutic areas."
The presentation will be available on the Foresee website after the conference.